Wall Street gets another reason to like Eli Lilly stock, and DuPont's spin is going to plan

Market Overview - The S&P 500 fell more than 1% and the Nasdaq dropped nearly 2% due to concerns over high valuations in the tech sector after a significant run [1] - Despite the declines, the S&P 500 is only about 1.5% off its record closing high from the previous week [1] Eli Lilly and Drug Pricing - Eli Lilly shares saw modest gains amid market declines, with reports suggesting a potential deal with the Trump administration regarding GLP-1 drug pricing [1] - The deal may involve reduced prices for the lowest doses of GLP-1 drugs in exchange for obesity coverage in Medicare and Medicaid programs [1] - Eli Lilly is positioned to negotiate due to its substantial investment in U.S. manufacturing [1] DuPont Separation - The early results from the DuPont separation are promising, with both new DuPont and spinoff Qnity Electronics showing positive trading sessions [1] - On a pre-spin basis, DuPont closed at $81.65, and the combined value of new DuPont and Qnity is approximately $88 per share, indicating an 8% increase in a declining market [1] - DuPont is set to release quarterly earnings on Thursday, with Qnity management providing a business update afterward [1] Upcoming Earnings Reports - Significant earnings reports are expected from Advanced Micro Devices, Arista Networks, Astera Labs, and Super Micro Computer [1] - Other notable earnings include Axon Enterprise, Cava, Toast, and Pinterest, with results from Novo Nordisk, McDonald's, Humana, Unity, and Sportradar due before Wednesday's opening bell [1] Employment Data - The October ADP employment report is anticipated, with a consensus estimate of a 37,500 increase in private employer jobs, a notable improvement from a 32,000 job decline in September [1]